AstraZeneca to investment $200 million in Chinese manufacturing plant; Novo Nordisk debuts Victoza
Anglo-Swedish drug major AstraZeneca ILSE: AZN) said this morning that it is investing $200 million in a new manufacturing facility, located in China Medical City (CMC), Taizhou, Jiangsu province. The new site, which represents AstraZeneca’s largest ever investment in a single manufacturing facility globally, will produce both intravenous and oral solid medicines for the company’s growing business in China.
Construction of the site is scheduled to be completed at the end of 2013 and will enable AstraZeneca to meet the growing demand for its products in China while expanding availability to people in the urban and rural communities who traditionally have had limited access to established medicines.
Adds to previous investments in China
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze